-
1 week ago | 
pharmaceutical-journal.com | Corrinne Burns
Pharmacies selling unlicensed, unregulated products must ensure these items are safe for patients and the public by seeking assurances from the product supplier and/or completing their own due diligence, according to Roz Gittins, chief pharmacy officer at the General Pharmaceutical Council (GPhC).
-
2 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
Community pharmacies in Wales will receive a one-off investment of £6m for the 2024/2025 financial year, the Welsh government has announced. The investment was announced in a letter sent to community pharmacies on 2 April 2025 from Andrew Evans, chief pharmaceutical officer for Wales, and Natalie Proctor, head of pharmacy and prescribing for the Welsh government.
-
2 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
The National Institute for Health and Care Excellence (NICE) has recommended a new combination treatment for locally advanced or metastatic hormone receptor (HR)-positive, HER 2-negative breast cancer for use on the NHS in England and Wales.
-
2 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
A scheme that allows pharmacies to demonstrate their work on sustainability at gold, silver or bronze level has been launched by the Royal Pharmaceutical Society (RPS). The free digital greener pharmacy toolkit, launched on 8 April 2025, will help community and hospital pharmacies monitor and reduce their environmental impact. Commissioned by NHS England and supported by the Greener NHS programme, the toolkit enables pharmacies to aim for bronze, silver and gold accreditation.
-
2 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
Patients in hospital emergency departments (EDs) who are able to self-administer time-critical medicines (TCMs) should be supported to do so, the Royal College of Emergency Medicine (RCEM) has said.
-
2 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
The Royal Pharmaceutical Society’s (RPS’s) Scottish Pharmacy Board (SPB) met at the Society’s Edinburgh office on 28 February 2025. On the agenda was the Society’s position on the facilitated sale of Pharmacy (P) medicines, discussions on public affairs and the Society’s work plan, and updates on constitution and governance proposals. Apologies were received from board members Catriona Sinclair and Josh Miller.
-
2 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
The Royal Pharmaceutical Society (RPS) English Pharmacy Board met on 26 February 2025 at the Society’s London office. The agenda for the meeting included the facilitated sale of Pharmacy (P) medicines, a review of Society constitution and governance proposals activity, and business plans for the year ahead.
-
2 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
The Royal Pharmaceutical Society (RPS) Welsh Pharmacy Board met on 21 February 2025 at the Society’s Cardiff office. On the agenda for the meeting was the facilitated sale of Pharmacy (P) medicines, a review of RPS constitution and governance proposals activity, and business plans for the year ahead. Apologies were received from board members Gareth Hughes, Rhian Lloyd-Evans and Dylan Jones.
-
3 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
Community pharmacies in England could offer “catch-up” human papillomavirus (HPV) vaccinations in efforts to eliminate cervical cancer. The proposals were outlined in updated plans from NHS England on cervical cancer elimination by 2040 — a goal that was originally set in November 2023. NHS England says that over 99% of cervical cancer cases are caused by HPV. The first HPV vaccine was launched in the UK in 2008 and was offered to all girls aged 12 or 13 years in secondary school.
-
3 weeks ago | 
pharmaceutical-journal.com | Corrinne Burns
Reimbursement for pharmacists employed under the Additional Roles Reimbursement Scheme (ARRS) in GP practices will rise by 1.7%, under the network contract directed enhanced service (DES) for 2025/2026, NHS England has announced. According to the contract, published on 1 April 2025, the maximum reimbursable amount for Band 7–8a clinical pharmacists in primary care networks (PCNs) and general practice on a national level will rise to £66,972, which is an increase from £65,838 in 2024.
